Aldeyra Therapeutics, Inc.
General ticker "ALDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $281.5M (TTM average)
Aldeyra Therapeutics, Inc. follows the US Stock Market performance with the rate: 36.3%.
Estimated limits based on current volatility of 1.7%: low 1.76$, high 1.93$
Factors to consider:
- Total employees count: 9 (-10.0%) as of 2024
- Top business risk factors: Regulatory and compliance, Quarterly fluctuations, Liquidity and credit risks, Acquisition/divestiture risks, Cybersecurity threats
- Current price 36.2% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.82$, 7.94$]
- 2026-12-31 to 2027-12-31 estimated range: [2.26$, 6.46$]
Financial Metrics affecting the ALDX estimates:
- Positive: with PPE of -9.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10698127.52 <= 0.07
- Positive: Investing cash flow per share per price, % of 15314993.30 > -0.65
- Positive: 42.60 < Shareholder equity ratio, % of 61.41 <= 64.25
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Negative: 0.01 < Interest expense per share per price, % of 0.61
Short-term ALDX quotes
Long-term ALDX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $42.79MM | $60.12MM | $35.27MM |
| Operating Income | $-42.79MM | $-60.12MM | $-35.27MM |
| Non-Operating Income | $5.25MM | $4.27MM | $1.42MM |
| Interest Expense | $2.07MM | $1.93MM | $1.91MM |
| R&D Expense | $29.46MM | $48.22MM | $25,662,855.00MM |
| Income(Loss) | $-37.54MM | $-55.85MM | $-33.85MM |
| Profit(Loss)* | $-37.54MM | $-55.85MM | $33,846,593.31MM |
| Stockholders Equity | $119.80MM | $71.00MM | $44.25MM |
| Assets | $148.33MM | $104.61MM | $72.06MM |
| Operating Cash Flow | $-30.33MM | $-43.21MM | $-33,345,682.00MM |
| Investing Cash Flow | $30.00MM | $-44.92MM | $47,736,288.00MM |
| Financing Cash Flow | $-1.27MM | $-0.17MM | $1,123,556.00MM |
| Earnings Per Share** | $-0.64 | $-0.94 | $563,574.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.